DNER and acute myeloid leukemia: Both preclinical and clinical studies have also found success in using a combinational approach of BET inhibitors with other approved AML therapies and the quickly developing landscape of these inhibitors offer unique opportunities for combination therapies that will be well tolerated clinically.